tiprankstipranks
Advertisement
Advertisement

MLTX Stock Latest News

MoonLake shareholders back director, auditor and compensation plans
Company AnnouncementsMoonLake shareholders back director, auditor and compensation plans
12d ago
8K
MLTX
MoonLake’s Phase 3 Sonelokimab Trial Reaches Completion in Hidradenitis Suppurativa
PremiumCompany Announcements
MoonLake’s Phase 3 Sonelokimab Trial Reaches Completion in Hidradenitis Suppurativa
13d ago
MLTX
Moonlake’s Phase 3 Hidradenitis Trial Hits Completion, Setting Up Key Catalyst for MLTX
PremiumCompany Announcements
Moonlake’s Phase 3 Hidradenitis Trial Hits Completion, Setting Up Key Catalyst for MLTX
13d ago
MLTX
MoonLake Secures Long-Term Manufacturing Capacity with Vetter Pharma
PremiumCompany Announcements
MoonLake Secures Long-Term Manufacturing Capacity with Vetter Pharma
20d ago
8K
MLTX
MoonLake Immunotherapeutics: Buy Rating Reiterated on De-Risked Path to 2026 BLA and Robust SLK Data; $30 Price Target Maintained
PremiumRatings
MoonLake Immunotherapeutics: Buy Rating Reiterated on De-Risked Path to 2026 BLA and Robust SLK Data; $30 Price Target Maintained
1M ago
MLTX
Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential
PremiumRatingsPhil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential
1M ago
MLTX
MoonLake advances sonelokimab toward BLA after positive FDA meeting
Premium
Company Announcements
MoonLake advances sonelokimab toward BLA after positive FDA meeting
1M ago
8K
MLTX
MoonLake price target raised to $45 from $40 at H.C. Wainwright
Premium
The Fly
MoonLake price target raised to $45 from $40 at H.C. Wainwright
1M ago
MLTX
MoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street
PremiumThe Fly
MoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street
1M ago
MLTX
MoonLake says aligned with FDA on submission plans for sonelokimab
PremiumThe Fly
MoonLake says aligned with FDA on submission plans for sonelokimab
1M ago
MLTX
MoonLake Immunotherapeutics reports Q1 EPS -98c vs. -91c last year
PremiumThe Fly
MoonLake Immunotherapeutics reports Q1 EPS -98c vs. -91c last year
1M ago
MLTX
Buy Rating on MoonLake: Sonelokimab’s Differentiated IL‑17 Profile and Late‑Stage HS Opportunity Support $40 Target
PremiumRatings
Buy Rating on MoonLake: Sonelokimab’s Differentiated IL‑17 Profile and Late‑Stage HS Opportunity Support $40 Target
2M ago
MLTX
Positive Risk-Reward and Strategic Momentum Underpin Buy Rating on MoonLake Immunotherapeutics
PremiumRatingsPositive Risk-Reward and Strategic Momentum Underpin Buy Rating on MoonLake Immunotherapeutics
2M ago
MLTX
MoonLake Buy Rating: Clear HS Approval Path, Priority Review Upside, and Underappreciated Multi-Indication Value
Premium
Ratings
MoonLake Buy Rating: Clear HS Approval Path, Priority Review Upside, and Underappreciated Multi-Indication Value
2M ago
MLTX
MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial
Premium
The Fly
MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial
3M ago
MLTX
MoonLake Immunotherapeutics management to meet with BTIG
PremiumThe Fly
MoonLake Immunotherapeutics management to meet with BTIG
3M ago
MLTX
MoonLake upgraded to Outperform from Underperform at Wolfe Research
PremiumThe Fly
MoonLake upgraded to Outperform from Underperform at Wolfe Research
3M ago
MLTX
Micron downgraded, Five Below upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Micron downgraded, Five Below upgraded: Wall Street’s top analyst calls
3M ago
MU
ADP
MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn
PremiumThe Fly
MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn
3M ago
MLTX
MoonLake Immunotherapeutics: Sonelokimab’s Differentiated IL‑17A/F Profile and Multibillion-Dollar Potential Underpin Buy Rating Despite HS Trial Concerns
PremiumRatingsMoonLake Immunotherapeutics: Sonelokimab’s Differentiated IL‑17A/F Profile and Multibillion-Dollar Potential Underpin Buy Rating Despite HS Trial Concerns
3M ago
MLTX
MoonLake price target raised to $70 from $45 at Clear Street
Premium
The Fly
MoonLake price target raised to $70 from $45 at Clear Street
3M ago
MLTX
MoonLake Immunotherapeutics price target raised to $40 from $32 at H.C. Wainwright
Premium
The Fly
MoonLake Immunotherapeutics price target raised to $40 from $32 at H.C. Wainwright
4M ago
MLTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >